Philip M Grant
Affiliation: Stanford University
- Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scoresPhilip Grant
Stanford University, Palo Alto, California, USA
Antimicrob Agents Chemother 52:4050-6. 2008....
- Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164Philip M Grant
Division of Infectious Diseases, Stanford University, Stanford, California 94305 5107, USA
J Infect Dis 206:1715-23. 2012..Immune reconstitution inflammatory syndrome (IRIS) reflects an aberrant immune response that can develop in human immunodeficiency virus-infected patients initiating antiretroviral therapy (ART). Its pathogenesis remains unclear...
- When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!Philip M Grant
Stanford University, Stanford, CA, USA
Curr HIV/AIDS Rep 9:251-8. 2012..Nonetheless, initiating ART early in acute care settings can be challenging to implement and requires a well-coordinated multidisciplinary team with expertise in ART management...
- Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistancePhilip M Grant
Stanford University, 300 Pasteur Drive, Room S 101, Stanford, CA 94305 5107, USA
Curr Opin Investig Drugs 11:901-10. 2010..With new-class and new-generation drugs, it is hoped that the lessons learned will be useful for limiting drug resistance and optimizing the use of ART for long-term management of HIV infection...
- Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infectionPhilip M Grant
Stanford University, Palo Alto, California, United States of America
PLoS ONE 5:e11416. 2010..However, few studies are prospective, and no study has evaluated the impact of the timing of ART when allocated randomly during an acute opportunistic infection (OI)...
- International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptasePhilip M Grant
Division of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Drive, S 101, Stanford, CA 94305 5107, USA
Antimicrob Agents Chemother 54:1520-5. 2010..In the presence of K65R, zidovudine and tenofovir are associated with similar reductions in HIV RNA levels. Given its tolerability, tenofovir may be the preferred agent over zidovudine even in the presence of the K65R mutation...
- The use of resistance testing in the management of HIV-1-infected patientsPhilip M Grant
Division of Infectious Diseases, Stanford University, Palo Alto, California, USA
Curr Opin HIV AIDS 4:474-80. 2009..Despite the widespread use of resistance testing, the clinician faces a number of challenges in optimally applying these technologies to antiretroviral management...
- Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of lifePhilip M Grant
Stanford University, Division of Infectious Diseases, Palo Alto, CA 94305 5107, USA
J Clin Virol 46:305-8. 2009..Raltegravir is a potential treatment option for virologically suppressed HIV-1 infected patients on enfuvirtide with injection site reactions...
- Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to losePhilip Grant
Division of Infectious Diseases and Geographic Medicine, 300 Pasteur Drive, Room S 101, Stanford, CA 94305 5107, USA
Curr HIV/AIDS Rep 6:63-7. 2009..Initiating ART in the hospitalized patient can be challenging and requires a well-coordinated multidisciplinary team with expertise in ART management...
- Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitorPhilip Grant
Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, California 94305 5107, USA
Clin Infect Dis 48:680-2. 2009....
- Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202Philip M Grant
Division of Infectious Diseases, Stanford University, Palo Alto, California
HIV Clin Trials 14:284-91. 2013..Individuals in the high screening viral load (VL) stratum (≥100,000 copies/mL) had increased rates of virologic failure with ABC/3TC...
- Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiationPhilip M Grant
Division of Infectious Diseases, Department of Medicine, Stanford University, Palo Alto, California
Clin Infect Dis 57:1483-8. 2013..Bone mineral density (BMD) decreases 2%-6% in the 2 years after antiretroviral therapy (ART) initiation. Pre-ART immune deficiency and early immune recovery may contribute to this loss...
- Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumoniaPaul E Sax
Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Clin Infect Dis 53:197-202. 2011..See the editorial commentary by Morris and Masur, on pages 203-204.)..
- Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Paul E Sax
Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
HIV Clin Trials 11:248-59. 2010..We project the life expectancies, costs, and incremental cost-effectiveness ratios (ICERs) of these strategies...
- Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164Philip M Grant
Stanford University, Stanford, California
HIV Clin Trials 15:133-9. 2014..Even with ART, mortality remains high during the first year after an OI in persons with advanced HIV infection, but it is unclear whether previous predictors of mortality remain valid in the current era...
- Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysisEran Bendavid
Division of General Internal Medicine, Stanford University, Stanford, USA
AIDS 25:211-20. 2011..the World Health Organization (WHO) recently changed its first-line antiretroviral treatment guidelines in resource-limited settings. The cost-effectiveness of the new guidelines is unknown...
- Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South AfricaSabina S Alistar
Department of Management Science and Engineering, Stanford University, Stanford, CA, USA
BMC Med 12:46. 2014..The epidemiologic impact and cost-effectiveness of combined prevention approaches in resource-limited settings remain unclear...
- Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendationsEugene T Richardson
Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA
Antiviral Res 103:88-93. 2014....